Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$2.50
-$0.38(-13.19%)
At close: 4:00 PM EDT
$2.50
-$0.38(-13.19%)
Day’s Range― - ―
52-Week Range$1.50 - $44.10
Previous CloseN/A
Volume56.72K
Average Volume (3M)105.98K
Market Cap
$3.91M
Enterprise Value$12.45
Total Cash (Recent Filing)$741.32K
Total Debt (Recent Filing)$6.56M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 12, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.55
Shares Outstanding1,836,324
10 Day Avg. Volume63,564
30 Day Avg. Volume105,978
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
Early Clinical ValidationPreliminary Phase 1 results provide early human validation for HCW9302’s Treg-focused mechanism, with activity and tolerability supporting dose selection and potential expansion into broader autoimmune and inflammatory indications.
Proprietary Cell Therapy AssetsRegaining worldwide rights restores strategic control over potentially valuable cell-therapy reagents and allows HCW to pursue partnerships across CAR-T and NK-cell markets without surrendering future economics to the former licensee.
Reduced LiabilitiesSettlement of disputed obligations and removal of property liens improve balance-sheet clarity, reduce legal overhang, and may preserve financial flexibility for research programs and relationships with critical operating partners.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flow shows that HCW’s development activities are not self-funding. Continued cash consumption will require additional capital or partnerships, increasing execution risk if funding becomes less available.
Unprofitable Early-Stage ModelHCW lacks an established commercial revenue base and remains deeply loss-making, so future value depends on clinical and regulatory progress rather than operating profitability. This limits financial resilience and makes setbacks costly.
Financing Dependence And DilutionRepeated private placements indicate reliance on external capital to advance the pipeline. New shares, pre-funded warrants, and common warrants can dilute existing holders and may constrain strategic flexibility before products generate revenue.
HCW Biologics News
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $1.50 and its highest was $44.10 in the past 12 months.
What is HCW Biologics’s market cap?
HCW Biologics’s market cap is $3.91M.
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is Nov 12, 2026 which is in 84 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on Aug 14, 2026. The company reported -$11.58 earnings per share for the quarter, missing the consensus estimate of -$1.98 by -$9.6.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Undervalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is -1.08.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 1,836,324 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of -$11.58 in its last earnings report, missing expectations of -$1.98. Following the earnings report the stock price went down -8.376%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HCW Biologics
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(100.00% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
12.71% Insiders
1.35% Mutual Funds
0.18% Other Institutional Investors
85.65% Public Companies and
Individual Investors